Glenmark Pharmaceuticals Ltd. has moved decisively to fend off alleged attempts by certain local firms in India to infringe on the local patents for its licensed diabetes therapy remogliflozin etabonate, which has had strong run in the country since its launch earlier this year.
Mumbai-based Glenmark had earlier this year moved the Delhi High Court and secured a restraining order against some companies, believed...







